CRIS Current Research Information System

GAMBINERI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.013
AS - Asia 6.708
EU - Europa 5.212
SA - Sud America 585
AF - Africa 388
Continente sconosciuto - Info sul continente non disponibili 351
OC - Oceania 20
Totale 23.277
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.833
SG - Singapore 1.797
CN - Cina 1.592
VN - Vietnam 1.544
IT - Italia 1.378
GB - Regno Unito 1.012
DE - Germania 612
HK - Hong Kong 543
SE - Svezia 465
BR - Brasile 433
IN - India 420
FR - Francia 350
RU - Federazione Russa 309
BD - Bangladesh 229
UA - Ucraina 190
IE - Irlanda 189
KR - Corea 141
NL - Olanda 124
ZA - Sudafrica 121
FI - Finlandia 108
JP - Giappone 106
CH - Svizzera 88
CA - Canada 84
TG - Togo 83
CI - Costa d'Avorio 80
EE - Estonia 66
BG - Bulgaria 63
AR - Argentina 61
AT - Austria 51
ID - Indonesia 44
PH - Filippine 43
IQ - Iraq 42
BE - Belgio 39
MX - Messico 36
SC - Seychelles 30
PL - Polonia 29
TR - Turchia 26
NG - Nigeria 24
EC - Ecuador 23
JO - Giordania 23
TH - Thailandia 23
ES - Italia 22
PK - Pakistan 20
TW - Taiwan 20
AU - Australia 17
GR - Grecia 16
IR - Iran 16
CL - Cile 15
AL - Albania 14
JM - Giamaica 13
LB - Libano 13
PY - Paraguay 13
PE - Perù 12
RO - Romania 12
CO - Colombia 11
HR - Croazia 11
UZ - Uzbekistan 11
EG - Egitto 10
MA - Marocco 10
SA - Arabia Saudita 10
VE - Venezuela 10
DK - Danimarca 9
HN - Honduras 9
MY - Malesia 9
SK - Slovacchia (Repubblica Slovacca) 9
CR - Costa Rica 8
IL - Israele 8
LT - Lituania 8
PT - Portogallo 7
ET - Etiopia 6
NO - Norvegia 6
CZ - Repubblica Ceca 5
LV - Lettonia 5
AE - Emirati Arabi Uniti 4
EU - Europa 4
GT - Guatemala 4
KE - Kenya 4
KZ - Kazakistan 4
NP - Nepal 4
RS - Serbia 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
GH - Ghana 3
HU - Ungheria 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PR - Porto Rico 3
SV - El Salvador 3
UY - Uruguay 3
BB - Barbados 2
GA - Gabon 2
GD - Grenada 2
KW - Kuwait 2
LC - Santa Lucia 2
NI - Nicaragua 2
PA - Panama 2
Totale 22.902
Salva come PNG Salva come JPEG
Città #
Singapore 1.187
Ashburn 873
Southend 835
Fairfield 740
San Jose 535
Hong Kong 502
Chandler 406
Woodbridge 369
Bologna 368
Seattle 343
Houston 337
Santa Clara 330
Wilmington 320
Ho Chi Minh City 317
Hanoi 295
Hefei 254
Council Bluffs 235
Princeton 231
Dong Ket 225
Ann Arbor 217
Cambridge 213
Beijing 208
Dublin 189
Los Angeles 188
Boardman 168
New York 149
Lauterbourg 134
Seoul 122
Jacksonville 120
Milan 116
Westminster 98
Nanjing 97
Hyderabad 89
Tokyo 88
Dallas 83
Lomé 83
Padova 83
Buffalo 82
Abidjan 80
Helsinki 77
Berlin 75
São Paulo 66
Sofia 60
Bern 59
Haiphong 56
Atlanta 55
Rome 55
Saint Petersburg 54
Guangzhou 50
Da Nang 45
Redondo Beach 45
San Diego 45
Jinan 44
The Dalles 44
Frankfurt am Main 43
Shenyang 43
Munich 39
Redwood City 39
Changsha 35
Hebei 35
Redmond 35
Bremen 34
Turin 34
Vienna 34
Phoenix 33
San Francisco 33
Orem 31
Mülheim 29
Amsterdam 28
Bengaluru 28
Shanghai 27
Chicago 26
Tianjin 26
Johannesburg 25
Nanchang 25
Norwalk 25
Brussels 24
Nuremberg 24
Denver 23
Des Moines 23
Falls Church 23
Zhengzhou 23
Abeokuta 22
Brooklyn 22
Dearborn 22
Jakarta 22
Baghdad 21
Hải Dương 21
Warsaw 21
Amman 20
Can Tho 20
Florence 19
London 19
Olalla 19
Toronto 19
Turku 19
Wuhan 19
Rimini 18
Boydton 17
Chennai 16
Totale 13.342
Salva come PNG Salva come JPEG
Nome #
Steroid reference intervals in women: influence of menopause, age and metabolism 1.377
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial 531
Impact of age, body weight and metabolic risk factors on steroid reference intervals in men 420
Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism 416
Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome 337
Defining hyperandrogenism in women with polycystic ovary syndrome: A challenging perspective 308
Behavioral, socio-environmental, educational and demographic correlates of excess body weight in Italian adolescents and young adults 267
Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women 252
Insulin sensitizers in polycystic ovary syndrome 249
SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial 245
Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning 237
Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone 236
Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry 236
17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. 231
Androgen Profiling by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women 225
Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism 225
A comprehensive approach in diagnosing the polycystic ovary syndrome 224
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. 220
New insights on diabetes in Turner syndrome: results from an observational study in adulthood 220
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome 218
Obituary: Renato Pasquali (1946-2019) 216
The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk 215
Efficacy of very low-calorie ketogenic diet with the Pronokal® method in obese women with polycystic ovary syndrome: a 16-week randomized controlled trial 213
In memoriam: Renato Pasquali (1946-2019) 213
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 203
Sex hormones, obesity and type 2 diabetes: is there a link? 201
A new interaction to come: Ghrelin and steroid hormones 198
Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states 198
Anti-müllerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? 192
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. 191
Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology 190
Psychological aspects of hyperandrogenic states in late adolescent and young women. 190
Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men. 189
New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study 188
The empowerment of translational research: lessons from laminopathies. 186
Clinical assessment of allostatic overload in adolescent and young women with hyperandrogenic states 183
Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction 182
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. 182
Evolution of cardiovascular risk factors and the risk for cardiovascular events in a Caucasian population with polycystic ovary syndrom 175
Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects 175
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. 174
Liraglutide and Renal Outcomes in Type 2 Diabetes. 174
Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. 173
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. 173
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. 171
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. 167
Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient 167
Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. 167
Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. 165
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin 163
Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls 163
No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours 162
Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. 160
The PCOS Phenotype in Unselected Populations (P-PUP) study: Ethnic variation in population-based normative cut-offs for defining hirsutism 159
Hirsutism and virilization 157
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. 156
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution 156
Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. 155
Metabolic effects of obesity on reproduction. 154
Sindrome dell'ovaio policistico e diabete di tipo 2 154
An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. 154
Molecular and phenotypical characterization of 10 families with 11ß-hydroxylase deficiency 152
Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. 150
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors 150
Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. 150
Prevalence and ultrasound patterns of testicular adrenal rest tumors in adults with congenital adrenal hyperplasia 150
Biomediators in polycystic ovary syndrome and cardiovascular risk 150
Is it possible to achieve an acceptable disease control by dietary therapy alone in Berardinelli Seip type 1? Experience from a case report 149
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 149
Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. 148
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. 147
Ghrelin and reproductive disorders. 147
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS 146
High serum concentration of total inhibin in polycystic ovary syndrome 146
The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE) 144
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. 141
Liraglutide and cardiovascular outcomes in type 2 diabetes 141
Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects 141
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors 141
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome 139
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS? 139
Quality of diet, screened by the Mediterranean diet quality index and the evaluation of the content of advanced glycation endproducts, in a population of high school students from Emilia Romagna 137
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. 137
The impact of obesity on reproduction in women with polycystic ovary syndrome. 136
Targeting insulin sensitivity in the treatment of polycystic ovary syndrome 136
Delphi consensus on the diagnostic criteria of polycystic ovary syndrome 135
Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction 134
Insulin-sensitizing agents in polycystic ovary syndrome. 132
Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students 132
The role of low-grade inflammation in the polycystic ovary syndrome. 130
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity 130
Radioiodine whole body scan pitfalls in differentiated thyroid cancer 129
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 127
Validation of an LC–MS/MS salivary assay for glucocorticoid status assessment: Evaluation of the diurnal fluctuation of cortisol and cortisone and of their association within and between serum and saliva 127
Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions 127
Mechanisms and treatment of obesity in polycystic ovary syndrome 125
Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C 125
New perspectives on the definition and management of polycystic ovary syndrome 123
Role of changes in dietary habits in polycystic ovary syndrome. 123
Parallel diurnal fluctuation of testosterone, androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in serum and saliva: validation of a novel liquid chromatography-tandem mass spectrometry method for salivary steroid profiling 123
Totale 19.366
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.431
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.431
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.838 0 57 119 132 193 94 71 165 73 134 478 322
2022/20232.170 233 295 93 305 148 131 69 114 350 165 158 109
2023/2024728 77 116 54 48 54 114 53 48 16 77 48 23
2024/20252.882 108 445 272 185 411 148 212 101 69 214 159 558
2025/20268.016 576 689 661 618 746 421 1.003 286 1.415 624 516 461
2026/20272.243 1.296 947 0 0 0 0 0 0 0 0 0 0
Totale 23.277